Scharf Investments LLC Has $11.08 Million Holdings in Haleon PLC Sponsored ADR $HLN

Scharf Investments LLC increased its holdings in Haleon PLC Sponsored ADR (NYSE:HLN) by 17.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,095,734 shares of the company’s stock after purchasing an additional 162,406 shares during the quarter. Scharf Investments LLC’s holdings in Haleon were worth $11,078,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. SOA Wealth Advisors LLC. grew its position in shares of Haleon by 60.5% in the 3rd quarter. SOA Wealth Advisors LLC. now owns 3,105 shares of the company’s stock valued at $28,000 after buying an additional 1,170 shares during the last quarter. Citizens National Bank Trust Department raised its position in shares of Haleon by 167.4% during the third quarter. Citizens National Bank Trust Department now owns 3,276 shares of the company’s stock worth $29,000 after acquiring an additional 2,051 shares during the last quarter. Atlantic Union Bankshares Corp lifted its stake in shares of Haleon by 293.7% in the third quarter. Atlantic Union Bankshares Corp now owns 3,697 shares of the company’s stock worth $33,000 after acquiring an additional 2,758 shares during the period. Stance Capital LLC acquired a new position in shares of Haleon in the third quarter worth approximately $34,000. Finally, Geneos Wealth Management Inc. boosted its holdings in Haleon by 33.0% in the first quarter. Geneos Wealth Management Inc. now owns 4,846 shares of the company’s stock valued at $50,000 after acquiring an additional 1,203 shares during the last quarter. 6.67% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have weighed in on HLN shares. Argus raised shares of Haleon to a “strong-buy” rating in a research report on Tuesday, March 17th. Morgan Stanley reaffirmed an “overweight” rating on shares of Haleon in a research note on Monday, December 15th. Wall Street Zen upgraded shares of Haleon from a “hold” rating to a “buy” rating in a research report on Saturday, March 21st. Jefferies Financial Group reissued a “buy” rating on shares of Haleon in a research note on Tuesday, January 20th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Haleon in a research report on Thursday, January 22nd. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $12.33.

Haleon Stock Performance

Shares of HLN stock opened at $10.00 on Wednesday. The firm has a 50 day moving average of $10.52 and a 200-day moving average of $9.88. The company has a market cap of $44.51 billion, a price-to-earnings ratio of 25.63 and a beta of 0.18. The company has a quick ratio of 0.71, a current ratio of 0.92 and a debt-to-equity ratio of 0.47. Haleon PLC Sponsored ADR has a 52 week low of $8.71 and a 52 week high of $11.42.

Haleon Dividend Announcement

The business also recently declared a dividend, which will be paid on Thursday, May 14th. Shareholders of record on Friday, April 10th will be paid a $0.1307 dividend. This represents a yield of 251.0%. The ex-dividend date of this dividend is Friday, April 10th. Haleon’s payout ratio is 28.21%.

About Haleon

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.